Publications, Pharmaceutical

Developing in vitro dissolution tests for orally inhaled drug products

The fate of inhaled drug substances, in vivo, is not well-understood but is believed to be dependent, to some extent, on dissolution characteristics.

This paper presents work to develop an in vitro apparatus and standardized methodology for quantifying the dissolution behavior of orally inhaled drug products. The developed solution incorporates an aerosol dose collection apparatus that collects the dose over a large area, and a modified USP Apparatus V Paddle Over Disc for dissolution testing. The discriminating ability of this solution was demonstrated via testing with a range of commercially available orally inhaled drug products (MDIs and DPIs). Good correlation was observed between in vivo mean absorption time and in vitro dissolution half-life. It is concluded that the developed solution has potential for compendial and QC testing and in the development of both branded and generic orally inhaled drug products.

Download Publication
10 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
13 Mar 2024

In Silico Modelling for Orally Inhaled Drug Development (OINDP)

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
7 Mar 2024

Sustainable Propellants and Bioequivalence Innovation in OINDPs

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 2 3 4 19
Back To Top